What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at ...

In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to ...

The stock's fall snapped a five-day winning streak.

According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why.

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Barclays lowered their target price on Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a report on Thursday, April 10th.

Barclays dropped their price objective on shares of Illumina from $100.00 to $77.00 and set an “underweight” rating for the company in a report on Thursday, April 10th.

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher (TMO) stock win upgrades. Read more here.

Shares of Illumina Inc. ILMN advanced 1.00% to $91.52 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.11% to 6,092.18 ...

Illumina’s Q1 Revenues Revenues amounted to $1.04 billion, down 1.4% year over year and flat on a constant-currency basis. However, the top line beat the Zacks Consensus Estimate by 0.2% ...

ILLUMINA Hedge Fund Activity We have seen 343 institutional investors add shares of ILLUMINA stock to their portfolio, and 468 decrease their positions in their most recent quarter. Here are some ...